European Opportunities Loom For Value Added Medicines
But Sales Still Lag US, With EU Legislative Review Set To Address Sector’s Need For Reform
Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in early November. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.
